Can I Participate?
Thank you for your interest in the intrigue clinical research study.
Deciphera Pharmaceuticals, LLC, is conducting the intrigue study to test the investigational drug DCC-2618 as a potential new treatment option for patients living with gastrointestinal stromal tumors (GIST). The study is being done to learn more about the safety of DCC-2618 and how well it works against cancer, as compared to Sutent® (sunitinib), in patients who have previously received imatinib.
To see if you may be eligible for the intrigue study, you will be asked a few questions. If the prescreening criteria are met, the information you provide will be shared with a site conducting the study.